ALGS - Aligos Therapeutics Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-44.32M

Cash

103.5M

Avg Qtr Burn

-20.34M

Short % of Float

2.04%

Insider Ownership

16.48%

Institutional Own.

66.60%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ALG-000184 (Capsid Assembly modulator) Details Chronic hepatitis B	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG-125755 Details Chronic hepatitis B, Liver disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG-055009 (THR-β Agonist) Details Non-alcoholic steatohepatitis	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG-010133 (S-antigen Transport-inhibiting Oligonucleotide Polymer) Details Chronic hepatitis B	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.